LivaNova PLC (LIVN)

NASDAQ: LIVN · IEX Real-Time Price · USD
52.99
-1.08 (-2.00%)
At close: Apr 12, 2024, 4:00 PM
51.95
-1.04 (-1.96%)
After-hours: Apr 12, 2024, 4:08 PM EDT
-2.00%
Market Cap 2.86B
Revenue (ttm) 1.15B
Net Income (ttm) 17.55M
Shares Out 53.96M
EPS (ttm) 0.32
PE Ratio 165.59
Forward PE 17.31
Dividend n/a
Ex-Dividend Date n/a
Volume 374,611
Open 53.71
Previous Close 54.07
Day's Range 52.75 - 54.26
52-Week Range 42.47 - 59.86
Beta 0.94
Analysts Buy
Price Target 64.00 (+20.78%)
Earnings Date May 1, 2024

About LIVN

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable p... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Feb 10, 1993
Employees 2,900
Stock Exchange NASDAQ
Ticker Symbol LIVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is $64.0, which is an increase of 20.78% from the latest price.

Price Target
$64.0
(20.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

LivaNova to Announce First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova will host a conference call to discuss its first-quarter 2024 results on Wed, May 1, 2024 at 1 p.m. London time (8 a.m. ET).

23 days ago - Business Wire

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its OSPREY clinical study has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.

24 days ago - Business Wire

LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.

5 weeks ago - Business Wire

LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.

5 weeks ago - Business Wire

LivaNova to Present at the Barclays Global Healthcare Conference

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present in a fireside chat at the Barclays Conference in Miami, Florida at 10:45 am ET on March...

Other symbols: BCS
5 weeks ago - Business Wire

LivaNova Reports Fourth-Quarter and Full-Year 2023 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024.

7 weeks ago - Business Wire

LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced its Board of Directors named Vladimir A. Makatsaria as the Company's CEO and a member of the Board of Directors, effective March 1.

2 months ago - Business Wire

LivaNova to Wind Down Advanced Circulatory Support Business Unit

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support Business Unit.

3 months ago - Business Wire

LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova will host a conference call to discuss its fourth-quarter and full-year 2023 results on Feb 21, 2024 at 8am ET.

3 months ago - Business Wire

LivaNova to Present at the Piper Sandler Healthcare Conference

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced Bill Kozy, Interim CEO and Board Chair will present in a fireside chat at Piper Sandler at 8:30 a.m. ET on November ...

5 months ago - Business Wire

LivaNova Reports Third-Quarter 2023 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC reported results for the quarter ended Sept. 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guid...

5 months ago - Business Wire

LivaNova to Present at the Stifel and Wolfe Healthcare Conferences

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced Bill Kozy, Interim CEO and Board Chair, will present at Stifel and Wolfe Healthcare Conferences on Nov. 14 & 15, respectiv...

6 months ago - Business Wire

LivaNova Board Appoints J. Christopher Barry as New Director

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced its Board of Directors today appointed J. Christopher Barry to the Board and Andrea Saia will retire from the Board on Dec...

6 months ago - Business Wire

LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced that Marco Dolci intends to retire as President of the Cardiopulmonary Business Unit by December 31, 2023.

7 months ago - Business Wire

LivaNova to Announce Third-Quarter 2023 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its third-quarter 2023 results on November 1, 2023 at 12 p.m. London time (8 a.m. Eastern Tim...

7 months ago - Business Wire

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced it received U.S. FDA 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor.

8 months ago - Business Wire

LivaNova to Present at the Baird Global Healthcare Conference

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced Bill Kozy, Interim CEO and Board Chair, will present at the Baird Global Healthcare Conference in New York on September 12...

8 months ago - Business Wire

LivaNova Reports Second-Quarter 2023 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidanc...

9 months ago - Business Wire

LivaNova to Announce Second-Quarter 2023 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m. London time (8 a.m. ET)...

10 months ago - Business Wire

LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study.

10 months ago - Business Wire

Primecap Management Pumps Up LivaNova Position

Media-shy investment firm PRIMECAP Management (Trades, Portfolio) revealed earlier this week it upped its stake in LivaNova PLC ( LIVN , Financial), which had an impact of 0.04% on the equity portfoli...

1 year ago - GuruFocus

LivaNova Reports First-Quarter 2023 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.

1 year ago - Business Wire

LivaNova Board of Directors Announce Leadership Changes

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. Effectiv...

1 year ago - Business Wire

LivaNova to Announce First-Quarter 2023 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, Ma...

1 year ago - Business Wire

LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance f...

1 year ago - Business Wire